Abstract
A series of human bronchial-carcinoma xenografts (3 small-cell anaplastic, 2 large-cell anaplastic and 3 adenocarcinomas) established in immune-suppressed mice were treated with combination chemotherapy based on clinical regimes. Xenograft response was assessed by the in situ endpoint of growth delay in s.c. tumours. Dose-response relationships of 3 triple-drug combinations and their component agents were explored, allowing the relative contributions of single agents in each combination to be assessed. The results demonstrate that the effects produced in the xenografts were generally consistent with clinical experience. Procarbazine, cyclophosphamide and CCNU stood out as the most effective drugs in small cell carcinoma, but were ineffective in the other histological types. These was some evidence for individuality of therapeutic response among the grafts, supporting the case for incorporating panels of histologically similar xenografts into primary drug-screening programmes to complement existing syngeneic rodent tumour systems.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Shorthouse, A., Jones, J., Steel, G. et al. Experimental combination and single-agent chemotherapy in human lung-tumour xenografts. Br J Cancer 46, 35–44 (1982). https://doi.org/10.1038/bjc.1982.162
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.162
This article is cited by
-
Haematological recovery following high-dose cyclophosphamide with autologous bone marrow transplantation
Cancer Chemotherapy and Pharmacology (1989)
-
Human tumor xenografts as model for drug testing
CANCER AND METASTASIS REVIEW (1988)
-
Development of new anti-cancer drugs
Medical Oncology and Tumor Pharmacotherapy (1986)